121 related articles for article (PubMed ID: 36722578)
1. Improving the understanding of PI-RADS in practice: characters of PI-RADS 4 and 5 lesions with negative biopsy.
Wang YH; Liang C; Zhu FP; Zhou TR; Li J; Wang ZJ; Liu BJ
Asian J Androl; 2023; 25(2):217-222. PubMed ID: 36722578
[TBL] [Abstract][Full Text] [Related]
2. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
3. Effectiveness of the «cognitive» biopsy in the diagnosis of prostate cancer in patients with a previous negative biopsy.
Barbas Bernardos G; Herranz Amo F; de Miguel Campos E; Luis Cardo A; Herranz Arriero A; Caño Velasco J; Cancho Gil MJ; Jara Rascón J; Mayor de Castro J; Hernández Fernández C
Actas Urol Esp (Engl Ed); 2019; 43(1):12-17. PubMed ID: 30131167
[TBL] [Abstract][Full Text] [Related]
4. Central zone lesions on magnetic resonance imaging: Should we be concerned?
Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
6. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
[TBL] [Abstract][Full Text] [Related]
7. Validation of the PI-RADS language: predictive values of PI-RADS lexicon descriptors for detection of prostate cancer.
Rudolph MM; Baur ADJ; Haas M; Cash H; Miller K; Mahjoub S; Hartenstein A; Kaufmann D; Rotzinger R; Lee CH; Asbach P; Hamm B; Penzkofer T
Eur Radiol; 2020 Aug; 30(8):4262-4271. PubMed ID: 32219507
[TBL] [Abstract][Full Text] [Related]
8. Interobserver Agreement and Positivity of PI-RADS Version 2 Among Radiologists with Different Levels of Experience.
Mussi TC; Yamauchi FI; Tridente CF; Tachibana A; Tonso VM; Recchimuzzi DR; de Souza Leão LR; Luz DC; Martins T; Baroni RH
Acad Radiol; 2019 Aug; 26(8):1017-1022. PubMed ID: 30268722
[TBL] [Abstract][Full Text] [Related]
9. Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement.
Arcot R; Sekar S; Kotamarti S; Krischak M; Michael ZD; Foo WC; Huang J; Polascik TJ; Gupta RT
Abdom Radiol (NY); 2022 Aug; 47(8):2917-2927. PubMed ID: 35674785
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
[TBL] [Abstract][Full Text] [Related]
11. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
12. Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1.
Apfelbeck M; Pfitzinger P; Bischoff R; Rath L; Buchner A; Mumm JN; Schlenker B; Stief CG; Chaloupka M; Clevert DA
Clin Hemorheol Microcirc; 2020; 76(4):503-511. PubMed ID: 33337358
[TBL] [Abstract][Full Text] [Related]
13. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
Yaxley AJ; Yaxley JW; Thangasamy IA; Ballard E; Pokorny MR
BJU Int; 2017 Nov; 120 Suppl 3():43-50. PubMed ID: 28749035
[TBL] [Abstract][Full Text] [Related]
14. In-bore MR prostate biopsy - initial experience.
Rembak-Szynkiewicz J; Wojcieszek P; Hebda A; Mazgaj P; Badziński A; Stasik-Pres G; Chmielik E; Bobek-Billewicz B
Endokrynol Pol; 2022; 73(4):712-724. PubMed ID: 35971938
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer.
Chu CE; Cowan JE; Lonergan PE; Washington SL; Fasulo V; de la Calle CM; Shinohara K; Westphalen AC; Carroll PR
Eur Urol Oncol; 2022 Oct; 5(5):537-543. PubMed ID: 33483265
[TBL] [Abstract][Full Text] [Related]
16. Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study.
Ahdoot M; Lebastchi AH; Long L; Wilbur AR; Gomella PT; Mehralivand S; Daneshvar MA; Yerram NK; O'Connor LP; Wang AZ; Gurram S; Bloom J; Siddiqui MM; Linehan WM; Merino M; Choyke PL; Pinsky P; Parnes H; Shih JH; Turkbey B; Wood BJ; Pinto PA;
Eur Urol Oncol; 2022 Apr; 5(2):176-186. PubMed ID: 33846112
[TBL] [Abstract][Full Text] [Related]
17. Post-MRI transrectal micro-ultrasonography of transition zone PI-RADS > 2 lesions for biopsy guidance.
Cornud F; Lefevre A; Camparo P; Barat M; Dumonceau O; Galiano M; Flam T; Soyer P; Barral M
Eur Radiol; 2022 Nov; 32(11):7504-7512. PubMed ID: 35451606
[TBL] [Abstract][Full Text] [Related]
18. Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?
Castellani D; Pace G; Cecchini S; Franzese C; Cicconofri A; Romagnoli D; Del Rosso A; Possanzini M; Paci E; Dellabella M; Pierangeli T
Urol Oncol; 2022 Oct; 40(10):452.e9-452.e16. PubMed ID: 35871992
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Analysis of Diffusion Weighted Imaging May Improve Risk Stratification of Prostatic Transition Zone Lesions.
Engel H; Oerther B; Reisert M; Kellner E; Sigle A; Gratzke C; Bronsert P; Krauss T; Bamberg F; Benndorf M
In Vivo; 2022; 36(5):2323-2331. PubMed ID: 36099133
[TBL] [Abstract][Full Text] [Related]
20. Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation.
Kan Y; Zhang Q; Hao J; Wang W; Zhuang J; Gao J; Huang H; Liang J; Marra G; Calleris G; Oderda M; Zhao X; Gontero P; Guo H
Eur Radiol; 2020 Nov; 30(11):6274-6284. PubMed ID: 32524222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
